Find research datasets worth reusing

Delayed Cerebral Ischaemia and Coagulation Alterations After Aneurysmal Subarachnoid Haemorrhage

ClinicalTrials.gov study NCT03985176. IPD Sharing: NO. Countries: 1. Publications: 1.

Point of Care Coagulation Testing in Patients Undergoing Major Surgery

ClinicalTrials.gov study NCT00656396. IPD Sharing: Not stated. Countries: 1. Publications: 1.

The Use of Ultrasonic Coagulating Shears Compared to Monopolar Electrocautery in Open Gastric Cancer Surgery

ClinicalTrials.gov study NCT01179750. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total

ClinicalTrials.gov study NCT00361894. IPD Sharing: Not stated. Countries: 19. Publications: 1.

The Role of Melatonin in the Regulation of Blood Coagulation

ClinicalTrials.gov study NCT01741389. IPD Sharing: Not stated. Countries: 1. Publications: 3.

Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study

ClinicalTrials.gov study NCT00986635. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Conventional Versus Point-of-care Based Coagulation Management

ClinicalTrials.gov study NCT00997841. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

ClinicalTrials.gov study NCT05313620. IPD Sharing: NO. Countries: 1. Publications: 58.

Blood Coagulation Profile After Liver Resection.

ClinicalTrials.gov study NCT05824013. IPD Sharing: Not stated. Countries: 1. Publications: 3.

Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma

ClinicalTrials.gov study NCT03634215. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery

ClinicalTrials.gov study NCT01416454. IPD Sharing: Not stated. Countries: 1. Publications: 7.

Effect of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers

ClinicalTrials.gov study NCT05006378. IPD Sharing: NO. Countries: 1. Publications: 1.

The Acute Effects of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers

ClinicalTrials.gov study NCT05272475. IPD Sharing: NO. Countries: 1. Publications: 1.

Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function

ClinicalTrials.gov study NCT02568696. IPD Sharing: Not stated. Countries: 1. Publications: 8.

Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial

ClinicalTrials.gov study NCT02330471. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

ClinicalTrials.gov study NCT05907629. IPD Sharing: UNDECIDED. Countries: 1. Publications: 87.

opencc-zeroOct 2020View details →

Coagulation profile of COVID-19 patients admitted to the ICU: an exploratory study

Background Coagulation abnormalities in COVID-19 patients have not been addressed in depth. Objective: To perform a longitudinal evaluation of coagulation profile of patients admitted to the ICU with COVID-19. Methods Conventional coagulation tests, rotational thromboelastometry (ROTEM), platelet function, fibrinolysis, antithrombin, protein C and S were measured at days 0, 1, 3, 7 and 14. Based on median total maximum SOFA score, patients were divided in two groups: SOFA ≤ 10 and SOFA > 10. Results Thirty patients were studied. Conventional coagulation tests remained unchanged during the study period, while the majority of patients exhibited a hypercoagulability state based on ROTEM. Fibrinogen levels were increased in both groups. ROTEM maximum clot firmness increased in both groups. ROTEM – FIBTEM maximum clot firmness was high in both groups, with a slight decrease from day 0 to day 14 in group SOFA ≤ 10 and a slight increase during the same period in group SOFA > 10. Fibrinolysis was low and decreased over time in all groups, with the most pronounced decrease observed in INTEM maximum lysis in group SOFA > 10. Protein C plasma levels increased over time in both groups, although patients in group SOFA > 10 exhibited lower values in comparison to patients in group SOFA ≤ 10. Conclusion COVID-19 patients have a pronounced hypercoagulability state, characterized by impaired endogenous anticoagulation and decreased fibrinolysis. The magnitude of coagulation abnormalities seems to correlate with the severity of organ dysfunction. The hypercoagulability state of COVID-19 patients was only detected by ROTEM.

opencc-zeroJul 2022View details →

Risk stratification and prognostic value of basic coagulation parameters among COVID-19 patients

Background: COVID-19 is a viral disease caused by a new strain of coronavirus. Currently, prognosis and risk stratification of COVID-19 patients is done by the disease's clinical presentation. Therefore, identifying laboratory biomarkers for disease prognosis and risk stratification of COVID-19 patients is critical for prompt treatment. Therefore, the main objective of this study was to assess the risk stratification and prognostic value of basic coagulation parameters and factors associated with disease severity among COVID-19 patients, Northwest Ethiopia. Methods: A follow-up study was conducted among conveniently recruited COVID-19 patients attended from March to June 2021. Socio-demographic and clinical data were collected using a structured questionnaire and checklist, respectively. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were analyzed by the HUMACLOT DUE PLUS® machine. Descriptive statistics were used to summarize the socio-demographic and clinical characteristics of study participants. Kruskal Wallis tests were used to compare the difference between parametric and non-parametric continuous variables, respectively. The area under the receiver operating characteristic curve (AUC) was used to evaluate the value of PT and APTT in the risk stratification and disease prognosis of COVID-19 patients. Ordinal logistic regression was used to identify the factors associated with disease severity and prognosis. A P-value < 0.05 was defined as statistically significant for all results. Result: Baseline PT at a cut-off value ≥ 16.25 seconds differentiated severe COVID-19 patients from mild and moderate patients (AUC: 0.89, 95% CI: 0.83–0.95). PT also differentiated mild COVID-19 patients from moderate and severe patients at a cut-off value ≤ 15.35 seconds (AUC: 0.90, 95% CI: 0.84–0.96). Moreover, alcohol drinkers were 3.52 times more likely chance of having severe disease than non-drinkers (95% CI: 1.41–8.81). A one-year increment in age also increased the odds of disease severity by 6% (95% CI: 3–9%). An increment of ≥ 0.65 seconds from the baseline PT predicted poor prognosis (AUC: 0.93, 0.87–0.99). Conclusions and recommendations: Prolonged baseline PT was observed in severe COVID-19 patients. Prolonged baseline PT was also predicted to worsen prognosis. An increase from the baseline PT was associated with worsen prognosis. Therefore, PT can be used as a risk stratification and prognostic marker in COVID-19 patients.

opencc-zeroDec 2015View details →

Data from: Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial

Objective: To determine whether treatment with recombinant human thrombomodulin (rhTM) increases survival among severe septic patients with sepsis-induced disseminated intravascular coagulation (DIC) Design: Single-center, open-label, randomized controlled trial Setting: Single tertiary hospital Participant: 92 severe septic patients with sepsis-induced DIC Interventions: Patients with DIC scores ≥4, as defined by the Japanese Association of Acute Medicine, were diagnosed with DIC. Randomization was performed by the envelope method. The treatment group (rhTM group, n = 47) was intravenously treated with rhTM within 24 h of admission (day 0), and the control group (n = 45) did not receive any anti-coagulants, except in cases of deep venous thrombosis and pulmonary embolism. Primary and secondary measurements: Data were collected on days 0 (admission), 1, 2, 3, 5, 7, and 10. The primary outcome was survival at 28 and 90 days. The secondary endpoints comprised changes in DIC scores, platelet counts, D-dimer, antithrombin III (ATIII), and C-reactive protein (CRP) levels, and Sequential Organ Failure Assessment (SOFA) scores. All analyses were conducted on an intent-to-treat basis. Main Results: The 28-day survival rates were 84 and 83% in the control and rhTM groups, respectively (p = 0.745, log rank test). The 90-day survival rates were 73% and 72% in the control and rhTM groups, respectively (p = 0.94, log rank test). Meanwhile, the rates of recovery from DIC (<4) were significantly higher in the rhTM group than in the control group (p = 0.001, log rank test). Relative change from baseline of D-dimer levels were significantly lower in the rhTM group than in the control group, on day 3 and 5. Conclusion: rhTM treatment decreased D-dimer levels and facilitated DIC recovery in severe septic patients with sepsis-induced DIC. However, the treatment did not improve survival in this cohort.